Back to results
Active, not recruitingPhase 3

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

IMA Clinical Research Phoenix

Phoenix, Arizona, United States

+197 additional locations

View on ClinicalTrials.gov